The Three Sourcing Paths, What Each Requires, and Which One Survives Scrutiny

Three Paths, Very Different Risk Profiles

Every weight loss clinic offering GLP-1 therapy has three lawful paths to weigh: one that can carry a patient program, one for clinical outliers, and one that is a research study. The paths are not equivalent, and the gap between them widened significantly after the shortage era ended.

For the broader business context, see The Metabolic Weight Loss Clinic Business Opportunity. This post covers sourcing specifically. To see how our team plans sourcing into a new weight loss clinic, read how we help founders open a medical weight loss clinic.

Path One: FDA-Approved Branded Product Through an Authorized Distributor

This is the sourcing method that carries no regulatory ambiguity. The clinic purchases FDA-approved product, such as Wegovy or Zepbound (both approved for chronic weight management), through an authorized distributor, with documented chain of custody from manufacturer to clinic.

The trade-off is cost. Branded GLP-1s carry high list prices: as published, checked October 2026, Wegovy's list price is $1,349.02 a package, against the lower prices compounded product carried during the shortage. That gap is largely why so many clinics built their programs on compounding in the first place.

What has changed is that manufacturer direct-pay programs have narrowed the effective patient cost meaningfully from peak list pricing: as published, checked October 2026, NovoCare lists Wegovy pens at $349 a month for most doses, and LillyDirect lists Zepbound vials from $299 a month. A clinic that assumed branded product was commercially impossible based on 2023 pricing should re-run that analysis, because the number it is working from is likely stale.

There is also a competitive argument. A clinic sourcing FDA-approved product can say so plainly to patients, and in a market where patients have read about counterfeit and substandard compounded product, that statement can convert.

A Note on Generics

There is no fully approved generic semaglutide or tirzepatide on the U.S. market as of October 2026: semaglutide has only a tentative approval, and tirzepatide has none. Liraglutide is different: FDA approved generic versions of Victoza in December 2024 and of Saxenda in August 2025. Any supplier offering discounted bulk semaglutide or tirzepatide described as generic is not selling what the label claims, and that offer should be treated as a reason to end the conversation rather than negotiate the price.

Path Two: Patient-Specific 503A Compounding

Compounding remains legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, but the conditions are narrow. The product must be compounded for an identified individual patient on receipt of a prescription, and it cannot be essentially a copy of a commercially available drug, which semaglutide and tirzepatide now are, since FDA declared their shortages resolved (tirzepatide on December 19, 2024, semaglutide on February 21, 2025). For the full regulatory picture, see our companion post, Is Compounded Semaglutide Still Legal.

The exception requires a prescriber to determine and document that a change produces a significant difference for that specific patient. Not a preference. Not a cost consideration. A documented clinical determination for an identified individual.

The FDA has also signaled a separate volume threshold for essentially-a-copy products, indicating it does not currently intend to act against a compounder filling four or fewer prescriptions of such a product per calendar month. For a clinic, the result is the same either way: this pathway can accommodate genuine clinical outliers, not a patient panel.

Clinics using this path should understand that much of the compliance burden sits with the prescribing provider, not only the pharmacy. A pharmacy marketing a combination formulation as a ready-made solution is not assuming that documentation risk on the clinic's behalf.

Path Three: An IRB-Governed Investigational Study

The third path changes the structure rather than working within the compounding exception. The clinic operates as a site in an FDA-regulated clinical study run under an IRB-approved protocol and an investigational new drug application (IND). It is a research commitment, not a cheaper sourcing route.

An IRB, such as WCG, reviews and approves the protocol, and the study operates under its continuing oversight. Altos Consulting Group helps clients prepare both the IRB application and the IND.

The honest accounting of what this costs and requires:

•A study drug cannot be promoted or sold commercially, and charging participants for it requires FDA's written authorization and is limited to direct cost

•Pricing for ACG's help with the IRB application and the IND is discussed once the scope is clear

•Approval is not guaranteed. No consulting firm can promise an IRB or FDA outcome, and applicants should plan for the possibility of a rejection or a request for substantial protocol revision

•Approval creates ongoing obligations (protocol adherence, documentation, adverse event reporting, and continuing review) that are real research duties, not paperwork formalities

This pathway suits clinics prepared to function as research sites. It does not suit clinics looking for a compliance label on an unchanged operating model.

The Path That Is Not a Path

Gray-market product labeled research use only, sourced from overseas suppliers or peptide vendors, is not a sourcing option for patient care. It sits outside every framework described above, it is an active enforcement target, and the product itself may not contain what the label claims.

Clinics sometimes rationalize this sourcing on price. The exposure is not proportional to the savings: it implicates the clinic, the medical director's license, and patient safety simultaneously.

Building Sourcing Into Clinic Operations

Whichever path a clinic uses, the operational requirements are similar. Document the sourcing relationship and keep the documentation current. Verify the pharmacy's licensing and accreditation status rather than accepting marketing claims. Ensure the medical director has reviewed and approved the sourcing arrangement in writing. And revisit the arrangement periodically, because this regulatory area has changed repeatedly and will continue to.

The Pricing Conversation Clinics Need to Have With Patients

Sourcing decisions eventually become patient conversations, and clinics that avoid the conversation until a patient raises it tend to handle it badly.

A patient who has been paying for compounded product and is told the clinic is moving to FDA-approved branded product will ask why. The answer that works is the accurate one: the shortage that made compounded product broadly available has ended, the regulatory basis for that pricing no longer exists, and the clinic is not willing to source outside a defensible framework. Patients tend to respond to that better than clinics expect, particularly in a market where coverage of counterfeit and substandard compounded product has been widespread.

What does not work is quietly switching sourcing without explanation, or implying that a gray-market product is equivalent to an approved one. Both damage trust in ways that are expensive to repair, and one of them creates liability.

Clinics should also prepare staff for the affordability question directly. Manufacturer direct-pay programs and savings arrangements have changed the effective cost picture meaningfully from peak list pricing. A front desk that can speak accurately to available options can convert patients that an unprepared one loses.

Documentation That Protects the Clinic

Regardless of path, a clinic should be able to produce, on request, the following: the identity and current licensing status of every pharmacy or distributor in its supply chain, the medical director's written approval of the sourcing arrangement, prescription-level documentation for any compounded product including prescriber determinations where required, and, for clinics operating under a study protocol, IRB approval, IND documentation, and evidence of continuing review compliance.

Clinics that maintain this documentation as a matter of routine handle regulatory inquiries as an administrative exercise. Clinics that assemble it reactively after an inquiry arrives handle it as a crisis.

ACG's supplier network includes 503A pharmacy partners for lawfully compoundable peptides and hormones, vetted for compliance. To learn more, see our clinic supplier network. For founders opening a new clinic, our launch program includes supplier access for a new wellness clinic. To discuss your clinic's sourcing specifically, book a free 30-minute strategy call.

Frequently Asked Questions

Can my clinic buy branded Wegovy or Zepbound wholesale?

Clinics purchase FDA-approved product through authorized distributors with documented chain of custody. The specific arrangement depends on the clinic's licensure and state requirements. Any supplier offering these products outside authorized distribution channels, particularly at unusual pricing, warrants immediate scrutiny rather than a purchase order.

Is a 503B outsourcing facility still an option for GLP-1s?

Not for semaglutide or tirzepatide. An outsourcing facility may compound from a bulk drug substance only if the substance is on FDA's 503B bulks list or the drug is on FDA's drug shortage list, and semaglutide and tirzepatide appear on neither list (FDA's compounding page, current as of April 2026). On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need. As of October 23, 2026, we found no final FDA determination on the proposal. If the exclusion is finalized, outsourcing facilities could compound semaglutide, tirzepatide, or liraglutide from bulk only while that drug is on FDA's drug shortage list; liraglutide is still on that list (FDA data of October 23, 2026).

Who carries the compliance risk in a compounded arrangement: the clinic or the pharmacy?

Both, but the prescriber determination requirement places significant burden on the clinic's prescribing provider specifically. The FDA guidance says that determination should be documented on the prescription. A pharmacy cannot make that determination on the provider's behalf, and marketing materials suggesting otherwise do not transfer the responsibility.

How often should a clinic revisit its GLP-1 sourcing arrangement?

At minimum quarterly, and immediately upon any FDA announcement affecting compounding status. This regulatory area produced multiple material changes between late 2024 and 2026, including shortage resolutions, enforcement deadlines, litigation outcomes, and a proposed bulks list exclusion. A sourcing decision made eighteen months ago is unlikely to still reflect current requirements.